

Wockhardt to market SAMMY – a process patented tablet for Osteoarthritis

Wockhardt signs in-licensing agreement with Italian firm to strengthen Pain relief portfolio

Mumbai, October 17, 2007

Pharmaceutical and biotechnology major Wockhardt Limited has signed an in-licensing agreement with the Italy-based Gnosis SpA to market SAME (S-adenosyl methionine), a process patented product for osteoarthritis. This will be marketed under the brand name SAMMY. As per ORG-IMS, the Indian market is worth Rs 270 crores for this product.

"SAMMY will complement our pain portfolio and further strengthen our osteoarthritis portfolio," said Wockhardt chairman Habil Khorakiwala, "We bring to India new products which will fill the gaps in the existing product portfolios.

Osteoarthritis (OA) is a condition in which low-grade inflammation results in pain in the joints, caused by wear and tear of cartilage. It is estimated that 80% of the population will have radiographic evidence of OA by age 65, which is alarming considering the increase of ageing population in India. SAMMY in addition to its pain relief effect plays an important role in cartilage formation and repair. Multi-countries clinical data have proven its efficacy and its role in osteoarthritis.

Gnosis SpA is an Italy-based advanced biotechnology company specialising in research and development of innovative process in the field of biotechnology.

Wockhardt Limited is a global pharmaceutical and biotechnology major with an innovative research and development programme. Wockhardt has global footprints including UK, France, Germany, Ireland and USA. Wockhardt employs 5500 people worldwide belonging to 14 different nationalities.